Print pageHome » Global Contract Manufacturing to Post Double Digit Growth
Global Contract Manufacturing to Post Double Digit Growth
PharmaManufacturing.com
06/28/2010
The global pharmaceutical industry is witnessing rapid advancements in processes and technology development, with automation emerging as an integral part of most manufacturing processes. Due to the implementation of stringent regulatory norms and spiraling costs, pharmaceutical companies are opting to outsource their manufacturing process to contract manufacturing organizations in order to improve efficiency and productivity. As per our new research report “Global Contract Manufacturing Market Analysis”, the pharmaceutical contract manufacturing market is expected to grow at a CAGR of around 12% during 2010-2012.
We have found that countries like India, Brazil, Ukraine, Mexico, China and Singapore have been emerging as the key destination for contract manufacturing. Several factors like low cost of manufacturing and highly developed infrastructure have boosted growth in the contract manufacturing industry. Our report provides complete analysis and information about the contract manufacturing industry of respective countries.
The key industry trends like biomanufacturing and changing quality procedures have been studied in the report. It is expected that these trends will drive the overall industry in future. We have found that pharmaceutical companies are increasingly adopting the concept of ‘virtual pharma’, wherein they retain the marketing rights while outsourcing all manufacturing activities and related processes. This allows companies to deliver goods at a faster rate than an internal plant would allow.
“Global Contract Manufacturing Market Analysis” provides extensive research and prudent analysis of the global contract manufacturing industry. It studies the past and present market trends to enable clients understand the market dynamics and opportunities for the expansion of business. The report highlights key industry issues and presents an unbiased picture of the industry. The report also includes information about the major players along with their business strategies at the country level markets. Thus, the report could be very valuable for investors while taking decision on investments.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM265.htm
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
